BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives Buy Rating from HC Wainwright

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $30.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 261.88% from the company’s current price.

Other research analysts have also issued research reports about the company. Needham & Company LLC increased their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. JMP Securities reiterated a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Finally, Evercore ISI lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $15.50.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $8.29 on Tuesday. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $9.50. The firm’s 50 day simple moving average is $8.03 and its 200-day simple moving average is $7.84. The firm has a market cap of $1.72 billion, a PE ratio of -13.59 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to the consensus estimate of $130.05 million. BioCryst Pharmaceuticals’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.28 earnings per share. Equities research analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in BioCryst Pharmaceuticals during the fourth quarter worth $33,000. Venturi Wealth Management LLC acquired a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $46,000. R Squared Ltd acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $48,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,322 shares during the last quarter. Finally, KBC Group NV grew its holdings in shares of BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.